Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? (DEFICIT) EQUITY (UNAUDITED)

v3.24.1.1.u2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY (UNAUDITED) - USD ($)
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022   3,654,119    
Beginning balance at Dec. 31, 2022 $ (3,008,054) $ 3,654 $ 63,726,057 $ (66,737,765)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense 131,579   131,579  
Exercise of pre-funded warrants (in shares)   66,566    
Exercise of pre-funded warrants 282,905 $ 66 282,839  
Conversion of multi-draw credit agreement - related party and accrued interest (in shares)   165,517    
Conversion of multi-draw credit agreement - related party and accrued interest 2,980,521 $ 166 2,980,355  
Net loss (5,167,520)     (5,167,520)
Ending balance (in shares) at Mar. 31, 2023   3,886,202    
Ending balance at Mar. 31, 2023 (4,780,569) $ 3,886 67,120,830 (71,905,285)
Beginning balance (in shares) at Dec. 31, 2023   12,349,243    
Beginning balance at Dec. 31, 2023 (2,131,818) $ 12,349 102,238,382 (104,382,549)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense 2,478,179   2,478,179  
Issuance of common stock and warrants, net of issuance costs (in shares)   15,713,664    
Issuance of common stock and warrants, net of issuance costs of $6,434,447 83,556,563 $ 15,714 83,540,849  
Net loss (5,019,531)     (5,019,531)
Ending balance (in shares) at Mar. 31, 2024   28,062,907    
Ending balance at Mar. 31, 2024 $ 78,883,393 $ 28,063 $ 188,257,410 $ (109,402,080)